Effects of entecavir and Shenxian Yiganling combination therapy on patients with HBeAg-positive chronic hepatitis B for 48 weeks / 中国中西医结合杂志

ABSTRACT

<p><b>OBJECTIVE</b>To evaluate of the efficacy and safety of entecavir (ETV) combined with Shenxian Yiganling (SY) versus ETV therapy on patients with HBeAg-positive chronic hepatitis B (CHB) for 48 weeks.</p><p><b>METHODS</b>One hundred and sixty-four CHB patients were assigned to two groups with the cohort study the ETV combined with SY treatment group and the ETV control group. The alanine aminotransferase (ALT), the undetectable HBV DNA level, and HBeAg negative conversion rate, and HBeAg serological negative conversion rate were observed before and after treatment.</p><p><b>RESULTS</b>At week 48, there was no significant difference in the normalization of ALT levels (70.00% vs 67.61%, P > 0.05) and undetectable HBV DNA levels (72.50% vs 73.24%, P > 0.05) between the two groups. There was significant difference in the HBeAg negative conversion rate (39.44% vs 23.75%) and HBeAg serological negative conversion rate (32.39% vs 15.00%) (both P < 0.05).</p><p><b>CONCLUSION</b>ETV combined with SY promoted the HBeAg serological negative conversion rate possibly through the recovery of the immune functions.</p>